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Though fish oils possess cardio-protective, anti-
inflammatory, and anti-cancer properties, their molec-
ular and biochemical mechanism of action is lacking.
In this issue of Chemistry & Biology, Tjonahen and
colleagues [1] identify a new metabolite of eicosapen-
tanoic acid, resolvin E2, produced by 5-lipoxygenase.
In trying to control inflammation, our traditional ap-
proach has been to target pathways thought to drive
the response. However, it’s becoming apparent that
while such pathways are pathogenic in inflammation,
paradoxically they can also be essential to bring about
its resolution and maintain normal physiological func-
tions [2]. Thus, it is the inhibition of inflammatory media-
tors with dual roles in health and disease that can result
in side effects. The adverse cardiovascular events aris-
ing from the inhibition of inducible cyclo-oxygenase
(COX-2), an enzyme that is supposedly pathogenic in in-
flammation, but protective in the cardiovascular system
[3], provide such an example. Besides COX, it seems the
lipoxygenases (LOXs) also possess an equally versatile
role in pathology and physiology with their stereotypical
pro-inflammatory nature increasingly overshadowed by
the emerging news that LOXs mediate the anti-inflam-
matory and cardio-protective effects of fish oils constit-
uents’ eicosapentaenoic acid (EPA) and docosahexa-
noic acid (DHA). In the latest installment to this story,
Tjonahen and colleagues [1] reveal a novel anti-inflam-
matory member of the resolvin family of EPA metabo-
lites, namely 5-LOX-derived resolvin E2 (RvE2). In doing
so, these and other authors are highlighting new anti-
inflammatory, cardio-protective, and anticancerous prop-
erties of LOXs, thereby sounding a now familiar note of
caution for those developing inhibitors of eicosanoid
metabolism.
Before discussing the resolvins, we must recall how
LOXs interact to form the lipoxins (LXs). The LX family
of eicosanoids were described as transcellular metabo-
lites of arachidonic acid (AA) generated via LOX-LOX
interaction, where AA is metabolized by either 15-LOX
in monocytes, eosinophils, or epithelial cells, with the in-
termediate eicosanoid taken up by neighboring leuko-
cytes (PMNs) and metabolized by their 5-LOX to LXA4
or LXB4 [4]. LXs may also be generated by the interac-
tion of leukocyte 5-LOX with platelet 12-LOX [5]. A third
pathway may be triggered by aspirin’s acetylation of
COX-2, resulting not in the inhibition of COX-2, but in
the generation of 15R-hydroxy-5,8,11,13-eicosatetrae-
noic acid (15R-HETE) from AA, which is metabolized
by leukocyte 5-LOX to epimeric forms of LXA4/B4 (15-
epi-LXA4/B4) [6].
Interest in fish oils and their metabolism down similar
transcellular pathways as AA to the LXs was triggered, in
part, by the outcome of the Greenland Eskimos study in
the 1970s, which reported that fish oil rich in u-3 EPA
and DHA was associated with a reduced incidence ofcardiovascular disease [7], while the GISSI prevention
study reported a 45% protection against sudden cardiac
death associated with taking u-3 polyunsaturated fatty
acids (PUFA) [8]. Of importance here, though each pa-
tient group in the GISSI study took daily low-dose aspi-
rin, the contribution of aspirin plusu-3 PUFA in the GISSI
trial was not taken in to consideration. Attempts were
then made to unravel whether and how fish oil-EPA and
DHA could be metabolized to protective eicosanoids
and if so, what their mechanism of action might be.
Using the murine air pouch model of self-resolving
PMN-driven inflammation, it was found that coadminis-
tration of EPA with aspirin triggered the 5-LOX-depen-
dent formation of 5S-hydroxy-eicosapentaenoic acid
(5S-HEPE) as well as 18R-HEPE [9]. Similarly, inflam-
matory PMNs stimulated ex vivo and treated with EPA
generated 18R-HEPE, 5S-HEPE along with a novel tri-
hydroxy-containing product, called resolvin E1 (RvE1,
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapen-
taenoic acid) [10]. Similar experiments with DHA also
generated novel metabolites including 17R-hydroxy-
DHA (17R-HDHA) in response to aspirin as well as
17S-HDHA and several related bioactive compounds
without aspirin, termed the resolvin D series and protec-
tins (for review see [11]). In addition to leukocytes, hu-
man endothelial cells expressing COX-2 or human
recombinant COX-2 incubated with EPA and aspirin
manufacture 18R-HEPE and 15R-HEPE, which when
further cultured with activated human PMNs were con-
verted into two classes of trihydroxy-containing EPEs,
namely 5S,12R,18R-triHEPE (RvE1) and 5S,6R,15R-
triHEPE (15-epi-LXA5) [9].
Thus, as with the LXs in the context of AA metabolism,
interactions between activated PMNs and vascular en-
dothelial cells at local sites of inflammation can initiate
the transcellular biosynthesis of anti-inflammatory lipid
mediators from EPA and DHA. Taken together, these
data show that aspirin treatment at local sites of inflam-
mation can convert EPA via acetylated COX-2 in vascu-
lar endothelial cells to 18R-HEPE and 15R-HEPE, which
is further metabolized by leukocyte 5-LOX to bioactive
RvE1 and 15-epi-LXA5. In terms of bioactivity, the LXs,
resolvins, and protectins all possess what might be
best described as anti-inflammatory, tissue protective,
and proresolution properties, as demonstrated in exper-
imental models of acute inflammation by controlling
the phagocytosis of apoptotic leukocytes, dampening
proinflammatory signals, and leukocyte trafficking [12].
In the current paper by Tjonahen and colleagues [1],
these authors report the 5-LOX-dependent formation of
a novel member of the resolvin E series generated during
RvE1 biosynthesis that shares similar anti-inflammatory
properties with RvE1. Derived from either human PMNs
or human recombinant 5-LOX, the structure of this novel
dihydroxyeicosanoid was found to be 5S, 18-dihydroxy-
eicosapentaenoic acid and called RvE2, the reduction
product of 5S-hydroperoxy, 18-hydroxy-EPE, an inter-
mediate in the biosynthetic pathway of RvE1. RvE2 pre-
vented PMN trafficking into a zymosan-induced peritoni-
tis when given either locally or systemically suggesting
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properties of this novel eicosanoid. These data further
highlight the pivotal role of 5-LOX in the generation of
anti-inflammatory lipid mediators.
Some products of LOX metabolism, the leukotrienes,
are undeniably proinflammatory while others are protec-
tive. For instance, 5-LOX-generated leukotriene B4 is
one of the most potent chemoattractants for PMNs
[13], a property that made it a target for drug develop-
ment either in the form of selective inhibition or as a
cotarget along with COX, so-called dual COX/LOX in-
hibitors. However, 5-LOX-derived LXs and resolvins are
emerging as some of the most important endogenous
regulators of the innate immune systems where, in addi-
tion to exerting proresolution effects, they are critical in
orchestrating inflammatory responses to parasite infec-
tion [14]. 5-LOX also enhances PMN phagocytic clear-
ance of bacteria from the lung [15], alveolar microbicidal
capacity [16], and resistance against Klebsiella-induced
pneumonia [17]. In this setting of infection and immunity,
5-LOX is essential to our immune defense system. Thus,
in the same way that COX-2 plays multiple roles in in-
flammation and normal physiology, 5-LOX can be proin-
flammatory or protective depending on the disease. It is
these findings that remind us that when developing in-
hibitors of AA metabolism, we must be highly cognizant
of the diverse and often opposing roles eicosanoids play
in host defense and that such inhibitors must be tailored
for diseases in which that pathway plays a pathogenic
role. This applies not only to the inflammatory response
to infection and/or injury, but also to the recently identi-
fied role LOXs play in carcinogenesis [18].
Advances in unveiling the molecular mechanisms be-
hind the benefits of aspirin and fish oils have under-
scored the critical importance that the enzymes (COX
and LOX) central to lipid mediators metabolism (AA,
EPA, and DHA) have in health and disease. Products of
these pathways were once maligned and the target of
drug discovery spawning the era of NSAID drug devel-
opment. While NSAIDs have provided us with great ben-
efit in terms of anti-inflammation and pain relief, they
were not without their side effects showing that some
LOX and COX products are protective. The LXs and
the recently discovered resolvins and protectins have
improved the reputation eicosanoids have gained over
the years in the field of inflammation research, and
pointed out the benefits of some COX or LOX products.
Thus, developing inhibitors for COX/LOX enzymes will
not be efficacious for all inflammation-driven diseases
and may even be detrimental to some. The point is
that eicosanoids are pathogenic in some diseases, pro-
tective in others while at the same time being essential
for normal physiological processes. It is this complexity
of function that must be borne in mind when developinginhibitors of eicosanoid metabolism in order to minimize
side effects.
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